Rescuing Cells.
Restoring Lives.
LifeRaft Biosciences is advancing Vepoloxamer, an investigational therapeutic targeting cell membrane damage, which is a key driver of death and disability across multiple high-value indications.
Vepoloxamer has been clinically tested, including in two Phase 3 trials, and was generally well tolerated in the 388-patient EPIC study. Starting with Radiation-Induced Severe Oral Mucositis for patients undergoing radiation therapy for head and neck cancer, a >$1B market with significant unmet need, the company has a clear and capital-efficient path to proof of concept.
Our Pipeline
A lead program in Radiation Induced Severe Oral Mucositis (RI-SOM) for patients being treated with radiation therapy for head and neck cancer, and a preclinical program in acute burns.
Pipeline →Publications
P188 (the commercially available excipient) and Vepoloxamer (our patent protected purified form, used as a therapeutic) studies have been published in peer-reviewed literature across cardiovascular, neurological, trauma and oncology-supportive-care indications for over three decades. Our Publications page links to key publications across a breadth of potential indications.
One Molecule. Many Opportunities.
The same membrane-sealing mechanism being studied to protect oral mucosa from radiation injury may apply wherever cell-membrane damage drives disease — across oncology supportive care, trauma, and stroke.
Vepoloxamer is an investigational drug and has not been approved by the U.S. Food and Drug Administration for any use.
Forward-Looking Statements: This page contains forward-looking statements, including statements regarding anticipated patent terms, prosecution outcomes, regulatory exclusivities, and clinical development plans. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks that patents may not issue or be enforceable, that clinical trials may not succeed, and that regulatory approvals may not be obtained. LifeRaft Biosciences undertakes no obligation to update these statements, except as required by applicable law.